Dr. Neil Curtis Dunavin, MD

Dr. Dunavin practices at Midwestern Regional Medical Center in Chicago, Illinois.

Dr. Dunavin's NPI, 1578798369, was assigned on May 21, 2009. Dr. Dunavin graduated from University of Kansas School of Medicine - Kansas City in 2009. Dr. Dunavin holds California license C162772.

Dr. Dunavin's primary practice is Midwestern Regional Medical Center, at 1430 Paysphere Cir, Chicago, IL 60674 in Cook County. The practice phone is (847) 731-4151.

Dr. Dunavin's primary practice is Midwestern Regional Medical Center in Chicago, Illinois. Dr. Dunavin is also affiliated with UCSF Helen Diller Medical Center at Parnassus Heights. The medical group on file is City of Hope Cancer Center Chicago. Dmand AI also links Dr. Dunavin to 1 more hospital and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dunavin practices, 2 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Dunavin's primary specialty in the NPI Registry, under taxonomy code 207RH0000X. The record also lists hematology. Dr. Dunavin is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dunavin's licenses on file in 5 states: California, Maryland, Kansas, Ohio and District of Columbia.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease, lung cancer, lymphoma, multiple myeloma and neutropenia among the conditions Dr. Dunavin treats.

CMS data shows 740 Medicare services from Dr. Dunavin across 7 procedure codes in 2024, for 179 Medicare patients. Medicare paid $43,942 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 179 Medicare patients who saw Dr. Dunavin in 2024. The largest group is 65 to 74, with 88 patients. 70% of them have high blood pressure, and 69% have high cholesterol. 28% are also on Medicaid. Their average risk score is 3.07, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dunavin's median patient age at 67, with 45% women.

In 2024, Dr. Dunavin wrote 871 Medicare Part D claims for 59 patients. 68% of them were for generic drugs. CMS names the drug for 661 of them, across 23 drugs with 11 or more claims each, at $4,688,026 in total drug cost. In 2023, CMS named 663 claims across 23 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Dunavin for performance year 2024, reported as part of a group. Dr. Dunavin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 23 papers to Dr. Dunavin, published from 2012 to 2021. 2015 was the busiest year, with 3. The most frequent topics are Hematopoietic Stem Cell Transplantation, T-Lymphocytes and Transplantation, Autologous. Dr. Dunavin has published most often in Bone Marrow Transplant. Dr. Dunavin's most frequent co-authors are Siddhartha Ganguly, MD, Sunil H. Abhyankar, MD and Prathima R. Anandi, MD.

Dmand AI links Dr. Dunavin to 4 clinical trials, 2 of them phase 1 studies. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Agranulocytosis.

CMS Open Payments shows 2 general payments to Dr. Dunavin from 2 drug and device companies from 2023 to 2024. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $25.

Dr. Dunavin graduated from University of Kansas School of Medicine - Kansas City in 2009.

Dr. Dunavin is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.